{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 31/80', '4.5.', 'CLINICAL STUDY POPULATION', '4.5.1. Inclusion Criteria', 'Subjects must meet all of the following inclusion criteria to be eligible for participation in this', 'study.', '1. Able and willing to comply with the protocol requirements and to sign the informed consent', 'form (ICF) as approved by the IEC/IRB, prior to any screening evaluations.', '2.', 'Male and female subjects >18 years at the time of consent who meet the American College', 'of Rheumatology (ACR)/EULAR 2013 diagnostic criteria (Van den Hoogen F. et al.,', \"2013) for systemic sclerosis with diffuse cutaneous involvement (according to LeRoy's\", 'criteria) and <5 years since the onset of the first systemic sclerosis manifestation other than', \"Raynaud's phenomenon.\", '3.', 'mRSS >10 at screening.', '4.', 'Active disease at screening, as defined by:', 'Worsening of skin thickening (>2 mRSS points) as assessed by mRSS measured at', 'screening versus a previous mRSS assessment made within 6 months prior to', 'screening, or', 'New areas of skin involvement within 6 months prior to screening as documented by', 'physician note, or', \"New-onset systemic sclerosis with symptoms or signs other than Raynaud's\", 'phenomenon within 2 years prior to screening, or', '>1 tendon friction rub (palpated in the finger flexors or extensors, wrist flexors or', 'extensors, olecranon bursa, shoulders, knees, anterior or posterior ankles with active', 'motion).', '5. Subject must be able and willing to comply with restrictions on prior and concomitant', 'medication as described in Section 4.5.3.2.', '6. Criterion modified per amendment.', '6.1', 'Female subjects of childbearing potential must have a negative serum', 'pregnancy test at screening and a negative urine pregnancy test at the baseline visit.', '7. Female subjects of childbearing potential or male subjects with female partners of', 'childbearing potential must be willing to comply with the contraceptive methods', 'described in Section 4.5.3.1 prior to the first dose of the IMP, during the clinical study,', 'and for at least 90 days after the last dose of the IMP for male subjects and 30 days after', 'the last dose of the IMP for female subjects.', '8.', 'A body mass index (BMI) between 18-35 kg/m\u00b2, inclusive, at screening.', 'Criterion modified per amendment for', 'only.', '8.1', 'A body mass index (BMI) between 18-30 kg/m\u00b2, inclusive, at screening.', '9. Judged to be in good health by the investigator based upon the results of a medical', 'history, physical examination, vital signs, 12-lead ECG, and fasting clinical laboratory', 'safety tests. Clinical laboratory safety test results must be within the reference ranges or', 'test results that are outside the reference ranges need to be considered non-clinically', 'significant in the opinion of the investigator.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 32/80', '4.5.2. Exclusion Criteria', 'Subjects meeting one or more of the following criteria cannot be enrolled in this clinical', 'study:', '1.', 'Known hypersensitivity to IMP ingredients or history of a significant allergic reaction', 'to any drug as determined by the investigator, such as anaphylaxis requiring', 'hospitalization.', '2.', 'Breastfeeding female or subject intending to become pregnant or breastfeed.', '3.', 'History of or a current immunosuppressive condition (e.g. human immunodeficiency', 'virus [HIV] infection, congenital, acquired).', '4.', 'Criterion modified per amendment.', '4.1.', 'Positive blood testing for hepatitis B surface antigen or hepatitis C virus', '(antibody, confirmed by hepatitis C virus RNA positivity). Note: Subjects with', 'a resolved hepatitis A at least 3 months prior to screening can be screened.', '5.', 'Criterion modified per amendment.', '5.1.', 'History of malignancy within the past 5 years (except for carcinoma in situ of', 'the uterine cervix, basal cell carcinoma of the skin that has been treated with', 'no evidence of recurrence, prostate cancer medically managed through active', 'surveillance or watchful waiting, and squamous cell carcinoma of the skin if', 'fully resected and ductal carcinoma in situ).', '6.', 'Criterion modified per amendment.', '6.1. Clinically significant abnormalities, in the opinion of the investigator, detected', 'on ECG at screening of either rhythm or conduction, QTcF >450 ms, or a', 'known long QT syndrome.', '7.', 'Underwent major surgery within 3 months prior to the baseline visit or have major', 'surgery planned during the study period.', '8.', 'Criterion modified per amendment.', '8.1.', 'Unstable cardiovascular, pulmonary, or other disease (other than systemic', 'sclerosis-related), in the opinion of the investigator, within 6 months prior to', 'the baseline visit (e.g. coronary heart disease, heart failure, stroke).', '9.', 'Previous or planned hematopoietic stem cell transplantation.', '10.', 'Subjects on phototherapy within 6 weeks prior to the baseline visit.', '11.', 'Severe pulmonary disease with FVC <45% of predicted within 6 months prior to the', 'baseline visit.', '12.', 'Chronic or ongoing active infectious disease, including tuberculosis (requiring', 'hospitalization or systemic treatment within 4 weeks prior to the baseline visit).', '13.', 'Criterion modified per amendment.', '13.1.', 'Taking medication known to be a substrate mainly metabolized by CYP2C8', '(Appendix 1) within 4 weeks or 5 half-lives of the drug (whatever is longer)', 'prior to the baseline visit.', '14.', 'Criterion modified per amendment.', '14.1.', 'Taking medication known to be strong inducers of CYP3A4 and also including', \"St. John's Wort (Appendix 2 2) within 4 weeks or 5 half-lives of the drug\", '(whatever is longer) prior to the baseline visit.', '15.', 'Criterion modified per amendment.', '15.1. Taking medication known to be strong inhibitors of CYP3A4 (Appendix 3)', 'within 4 weeks or 5 half-lives of the drug (whatever is longer) prior to the', 'baseline visit.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}